Veteran International Health Care Executive Appointed CEO of BeneChill(R)

SAN DIEGO and STOCKHOLM, June 4, 2010 - Amgen executive Alan Raffensperger has been appointed the new Chief
Executive Officer of BeneChill, a privately held medical device company
launching its first product, a novel cooling device for use by emergency
response teams in the field, later this year in Europe. With more than 25
years of experience in the pharmaceutical, biotechnology, medical device and
diagnostic industries, Mr. Raffensperger joins BeneChill from his post as
Executive Director and Franchise Head of Nephrology for Amgen, a global
biopharmaceutical company. He joined Amgen in 2005 as General Manager of the
Nordic and Baltic Region, overseeing operations in eight countries from his
Sweden base.

(Photo: photos.prnewswire.com/prnh/20100604/LA15970)

(Photo: www.newscom.com/cgi-bin/prnh/20100604/LA15970)

"As we prepare to launch our lead RhinoChill(TM) product in Europe, it
was critical that we recruit a seasoned, well-rounded CEO with big pharma
experience and the sensitivity to a smaller company," said Denise Barbut,
M.D., Executive Chair and founder of BeneChill. "Alan's stellar track record
and experience in product development, sales and marketing will enable us to
achieve our business goals."

Prior to Amgen, Mr. Raffensperger was with Hoffman La Roche for ten years
with his most recent position as Head of Pharmaceutical Marketing and Sales
for Roche in Sweden. Previously, he was the CEO for Swedemed, a
privately-held developer of an advanced ultrasonic surgery system. He began
his career with Pharmacia, first in sales in the U.S. and then product
management in Sweden.

Earlier in his career, Mr. Raffensperger was a paramedic for National
Hospital in Arlington, VA and notes that his experience in cardiovascular and
trauma emergency care provides a solid foundation for understanding the need
for BeneChill's cooling devices in the field. He received his Bachelor of
Science degree in Emergency Health Sciences Management from the University of
Maryland and was an MBA candidate at George Washington University. He is a
nationally registered EMT-paramedic.

BeneChill(R) is a privately held medical device company that develops
novel, rapid cooling systems to improve survival after cardiac arrest.
RhinoChill(TM) can be administered quickly and directly to the brain by a
proprietary portable system that uses a nasal catheter to deliver a rapid
evaporative coolant and will be marketed in Europe later this year. With
corporate headquarters in San Diego, CA, BeneChill will be opening offices in
Switzerland.

Lynn Rubenson, +1-858-922-9201, lynnrubenson at yahoo.com, for BeneChill